AlgoNomics Granted Patent Rights for Epibase
News Mar 08, 2007
AlgoNomics NV has announced that notice of grant has been received from the European Patent Office for a key patent covering its Epibase® technology.
Epibase® is applied for the immunogenicity screening and optimization of biotherapeutics, such as therapeutic antibodies, biosimilars and vaccines.
The patent relates to AlgoNomics’ method to identify T-cell epitopes through the physicochemical interactions of the epitopes with their HLA Class-I and Class-II receptors.
Philippe Stas, COO of AlgoNomics: “We provide the state of the art in modeling of proteins, and this patent confirms our pioneering role in the field of immunogenicity screening and epitope identification.”
According to Dr. Lasters, CEO of AlgoNomics, “This patent confirms our innovative position as a world-leader in immunogenicity assessment of protein therapeutics”.
The patent titled “Method for predicting the binding affinity of MHC/peptide complexes” was filed in 2003, and can be found under European patent no. 1516275.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.